Analysts forecast that Ultragenyx Pharmaceutical (NASDAQ:RARE) will report $4.50 million in sales for the current fiscal quarter, Zacks reports. Ten analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from $2.00 million to $13.35 million. The company is scheduled to announce its next earnings report on Thursday, July 26th.
On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $31.82 million for the current fiscal year, with estimates ranging from $16.66 million to $65.93 million. For the next fiscal year, analysts anticipate that the firm will report sales of $84.48 million per share, with estimates ranging from $58.30 million to $104.26 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.81. The company had revenue of $10.68 million during the quarter, compared to analysts’ expectations of $56.58 million. During the same period last year, the firm earned ($1.63) earnings per share.
Several equities research analysts have issued reports on RARE shares. Bank of America boosted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $72.00 in a research report on Tuesday, April 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $74.00 price target (down previously from $85.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 21st. Robert W. Baird reaffirmed a “buy” rating and issued a $70.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 23rd. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, April 14th. Finally, SunTrust Banks raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the stock from $41.67 to $55.00 in a research report on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $70.06.
In related news, EVP Karah Herdman Parschauer sold 1,465 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The shares were sold at an average price of $60.00, for a total transaction of $87,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of RARE. Covington Capital Management bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $102,000. Rockefeller Capital Management L.P. bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $108,000. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 1,246.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 3,030 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $205,000. Finally, B. Riley Financial Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $213,000. Hedge funds and other institutional investors own 95.47% of the company’s stock.
Ultragenyx Pharmaceutical traded up $1.12, hitting $65.30, during trading hours on Friday, MarketBeat Ratings reports. The company had a trading volume of 423,200 shares, compared to its average volume of 537,021. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -8.71 and a beta of 1.83. Ultragenyx Pharmaceutical has a 1 year low of $41.67 and a 1 year high of $71.99.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.